摘要Dear Editor,Previous studies have proved that regulatory T cell(Treg)insufficiency contributed to the development of autoimmune conditions including systemic lupus erythematosus(SLE).Con-ventional immunosuppressive treatment was reported to down-regulate beneficial Tregs together with pathogenic effector immune cells,which may impede a rapid achievement of optimal therapeutic effects.1,2 As the most effective and widely applied immunosuppressive medication for SLE,glucocorticoid treatment has the risk of excessive suppression of immune cell subsets.
作者单位Department of Rheumatology and Immunology,Clinical Immunology Center,Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis(BZ0135),Peking University People's Hospital,No.11 Xizhimen South Street,100044 Beijing,China[1]Department of Rheumatology,Beijing Children's Hospital,Capital Medical University,National Centre for Children's Health,100045 Beijing,China[2]Department of Rheumatology and Immunology,Clinical Immunology Center,Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis(BZ0135),Peking University People's Hospital,No.11 Xizhimen South Street,100044 Beijing,China;Peking-Tsinghua Center for Life Science,Beijing,China[3]
换一批
换一批
